Hyperactive Ras as a therapeutic target in neurofibromatosis type 1

American Journal of Medical Genetics - Seminars in Medical Genetics

Volumn 89, Issue 1, 1999, Pages 14-22

  Weiss, Brian ^a   Bollag, Gideon ^c   Shannon, Kevin ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c NONE

Author keywords

Experimental therapeutics; Neurofibromatosis type 1; Ras

Indexed keywords

ALLELE; ARTICLE; GENE EXPRESSION; HUMAN; NEUROFIBROMATOSIS; ONCOGENE RAS; PRIORITY JOURNAL; PROTEIN PROCESSING; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR GENE;

DRUG DESIGN; GENES, NEUROFIBROMATOSIS 1; GTPASE-ACTIVATING PROTEINS; HUMANS; NEUROFIBROMATOSIS 1; PROTEINS; PROTO-ONCOGENE PROTEINS P21(RAS); RAS GTPASE-ACTIVATING PROTEINS; RAS PROTEINS; SEQUENCE DELETION; SIGNAL TRANSDUCTION;

EID: 0033605482     PISSN: 01487299     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-8628(19990326)89:1<14::AID-AJMG5>3.0.CO;2-4     Document Type: Article

References (103)

1. Alessi DR, James SR, Downes CP, Holmes AB, Gaffney PR, Reese CB, Cohen P. 1997. Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase B α. Curr Biol 7:261-269.
2. Andersen LB, Fountain JW, Gutmann DH, Tarle SA, Glover TW, Dracopoli NC, Housman DE, Collins FS. 1993. Mutations in the neurofibromatosis 1 gene in sporadic malignant melanoma cell lines. Nature Genet 3: 118-121.
3. Ballester R, Marchuk D, Boguski M, Saulino A, Letcher R, Wigler M, Collins F. 1990. The NF1 locus encodes a protein functionally related to mammalian GAP and yeast IRA proteins. Cell 63:851-859.
4. Barrington RE, Subler MA, Rands E, Omer CA, Miller PJ, Hundley JE, Koester SK, Troyer DA, Bearss DJ, Conner MW, Gibbs JB, Hamilton K, Koblan KS, Mosser SD, O'Neill TJ, Schaber MD, Senderak ET, Windle JJ, Oliff A, Kohl NE. 1998. A farnesyltransferase inhibitor induces tumor regression in transgenic mice harboring multiple oncogenic mutations by mediating alterations in both cell cycle control and apoptosis. Mol Cell Biol 18:85-92.
5. Bar-Sagi D, Feramisco JR. 1985. Microinjection of the ras oncogene protein into PC12 cells induces morphological differentiation. Cell 42:841-848.
6. Basu TN, Gutmann DH, Fletcher JA, Glover TW, Collins FS, Downward J. 1992. Aberrant regulation of ras proteins in malignant tumour cells from type 1 neurofibromatosis patients. Nature 356:713-715.
7. Bernards A. 1995. Neurofibromatosis type 1 and Ras-mediated signaling: filling in the GAPs. Biochim Biophys Acta 1242:43-59.
8. Boguski M, McCormick F. 1993. Proteins regulating Ras and its relatives. Nature 366:643-653.
9. Bollag G, Clapp DW, Shih S, Adler F, Zhang Y, Thompson P, Lange BJ, Freedman MH, McCormick F, Jacks T, Shannon K. 1996. Loss of NF1 results in activation of the Ras signaling pathway and leads to aberrant growth in murine and human hematopoietic cells. Nature Genet 12:144-148.
10. Bourne HR, Sanders DA, McCormick F. 1990. The GTPase superfamily: a conserved switch for diverse cell functions. Nature 348:125-132.
11. Bowtell D, Fu P, Simon M, Senior P. 1992. Identification of murine homologues of the Drosophila son of sevenless gene: potential activators of ras. Proc Acad Acad Sci U S A 89:6511-6515.
12. Brannan CI, Perkins AS, Vogel KS, Ratner N, Nordlund ML, Reid SW, Buchberg AM, Jenkins N. Parada L, Copeland N. 1994. Targeted disruption of the neurofibromatosis type 1 gene leads to developmental abnormalities in heart and various neural crest-derived tissues. Genes Dev 8:1019-1029.
13. Broek D, Toda T, Michaeli T, Levin L, Birchmeier C, Zoller M, Powers S, Wigler M. 1987. The S. cerevisiae CDC25 gene product regulates the RAS/adenylate cyclase pathway. Cell 48:789-799.
14. Buchberg A, Cleveland L, Jenkins N, et al. 1990. Sequence homology shared by neurofibromatosis type-1 gene and IRA-1 and IRA-2 negative regulators of the RAS cyclic AMP pathway. Nature 347:291-294.
15. Buday L, Downward J. 1993. Epidermal growth factor regulates p21ras through the formation of a complex of receptor, Grb2 adapter protein, and Sos nucleotide exchange factor. Cell 73:611-620.
16. Casey PJ, Seabra MC. 1996. Protein prenyltransferases. J Biol Chem 271: 5289-5292.
17. Cawthon RM, Weiss R, Xu GF, Viskochil D, Culver M, Stevens J, Robertson M, Dunn D, Gesteland R, O'Connell P, White R. 1990. A major segment of the neurofibromatosis type 1 gene: cDNA sequence, genomic structure, and point mutations. Cell 62:193-201.
18. Cen H, Papageorge AG, Zippel R, Lowy DR, Zhang K. 1992. Isolation of multiple mouse cDNAs with coding homology to Saccharomyces cerevisiae CDC25: identification of a region related to Bcr, Vav, Dbl and CDC24. EMBO J 11:4007-4015.
19. Clarke S. 1992. Protein isoprenylation and methylation at carboxyl-terminal cysteine residues. Annu Rev Biochem 61:355-386.
20. Clarke S. 1993. Protein methylation. Curr Opin Cell Biol 5:977-983.
21. Clarke S, Vogel JP, Deschenes RJ, Stock J. 1988. Posttranslational modification of the Ha-ras oncogene protein: evidence for a third class of protein carboxyl methyltransferases. Proc Natl Acad Sci U S A 85:4643-4647. (Published erratum appears in Proc Natl Acad Sci U S A 1988;85(20):7556.)
22. Colman SD, Williams CA, Wallace MR. 1995. Benign neurofibromas in type 1 neurofibromatosis (NF1) show somatic deletions of the NF1 gene. Nature Genet 11:90-92.
23. Cox AD, Der CJ. 1997. Farnesyltransferase inhibitors and cancer treatment: targeting simply ras? Biochim Biophys Acta 1333:F51-F71.
24. Crews CM, Erikson RL. 1993. Extracellular signals and reversible protein phosphorylation: what to Mek of it all. Cell 74:215-217.
25. ras contributes to malignant tumor growth in von Recklinghausen (type 1) neurofibromatosis. Cell 69:265-273.
26. Dudley DT, Pang L, Decker SJ, Bridges AJ, Saltiel AR. 1995. A synthetic inhibitor of the mitogen-activated protein kinase cascade. Proc Natl Acad Sci U S A 92:7686-7689.
27. Ebinu JO, Bottorff DA, Chan EY, Stang SL, Dunn RJ, Stone JC. 1998. RasGRP, a Ras guanyl nucleotide- releasing protein with calcium- and diacylglycerol-binding motifs. Science 280:1082-1086.
28. Egan SE, Giddings BW, Brooks MW, Buday L, Sizeland AM, Weinberg RA. 1993. Association of Sos Ras exchange protein with Grb2 is implicated in tyrosine kinase signal transduction and transformation. Nature 363:45-51.
29. Emanuel PD, Shannon KM, Castleberry RP. 1996. Juvenile myelomonocytic leukemia: molecular understanding and prospects for therapy. Mol Med Today 2:468-475.
30. Fam NP, Fan WT, Wang Z, Zhang LJ, Chen H, Moran MF. 1997. Cloning and characterization of Ras-GR.F2, a novel guanine nucleotide exchange factor for Ras. Mol Cell Biol 17:1396-1406.
31. Farnsworth CL, Freshney NW, Rosen LB, Ghosh A, Greenberg ME, Feig LA. 1995. Calcium activation of Ras mediated by neuronal exchange factor Ras-GRF. Nature 376:524-527.
32. Favata MF. Horiuchi KY, Manos EJ, Daulerio AJ, Stradley DA, Feeser WS, Van Dyk DE, Pitts WJ, Earl RA, Hobbs F, Copeland RA, Magolda RL, Scherle PA, Trzaskos JM. 1998. Identification of a novel inhibitor of mitogen-activated protein kinase kinase. J Biol Chem 273:18623-18632.
33. Feig LA, Urano T, Cantor S. 1996. Evidence for a Ras/Ral signaling cascade. Trends Biochem Sci 21:438-441.
34. Finegold AA, Johnson DI, Farnsworth CC, Gelb MH, Judd SR, Glomset JA, Tamanoi F. 1991. Protein geranylgeranyltransferase of Saccharomyces cerevisiae is specific for Cys-Xaa-Xaa-Leu motif proteins and requires the CDC43 gene product but not the DPR1 gene product. Proc Natl Acad Sci U S A H8:4448-4452.
35. Franke TF, Yang SI, Chan TO, Datta K, Kazlauskas A, Morrison DK, Kaplan DR, Tsichlis PM. 1995. The protein kinase encoded by the Akt proto-oncogene is a target of the PDGF-activated phosphatidylinositol 3-kinase. Cell 81:727-736.
36. Gibbs JB, Oliff A. 1997. The potential of farnesyltransferase inhibitors as cancer chemotherapeutics. Annu Rev Pharmacol Toxicol 37:143-166.
37. Gibbs JB, Oliff A, Kohl NE. 1994. Farnesyltransferase inhibitors: Ras research yields a potential cancer therapeutic. Cell 77:175-178.
38. Glover TW, Stein CK, Legius E. Andersen LB, Brereton A, Johnson S. 1991. Molecular and cytogenetic analysis of tumors in von Recklinghausen neurofibromatosis. Genes Chromosom Cancer 3:62-70.
39. Guha A, Lau N, Huvar I, Gutmann D, Provias J, Pawson T, Boss G. 1996. Ras-GTP levels are elevated in human NF1 peripheral nerve tumors. Oncogene 12:507-513.
40. Guo HF, The I, Hannan F, Bernards A, Zhong Y. 1997. Requirement of Drosophila NF1 for activation of adenylyl cyclase by PACAP38-like neuropeptides. Science 276: 795-798.
41. Iversen P, Lewis I, Turczynowicz S, Hasle H, Niemeyer C., Schmiegelow K, Bastiras S, Biondi A, Hughes TP, Lopez AF. 1997. Inhibition of granulocyte-macrophage colony-stimulating factor prevents dissemination and induces remission of juvenile myelomonocytic leukemia in engrafted immunodeficient mice. Blood 90:4910-4917.
42. Iversen P, Rodwell RL, Pitcher L, Taylor KM, Lopez AF. 1996. Inhibition of proliferation and induction of apoptosis in JMML cells by the granulocyte-macrophage colony-stimulating factor analogue E21R. Blood 88:2634-2639.
43. Jacks T, Shih S, Schmitt EM, Bronson RT, Bernards A, Weinberg RA. 1994. Tumorigenic and developmental consequences of a targeted Nf1 mutation in the mouse. Nature Genet 7:353-361.
44. Johnson MR, Look AT, DeClue JE, Valentine MB, Lowy DR. 1993. Inactivation of the NF1 gene in human melanoma and neuroblastoma cell lines without impaired regulation of GTP-Ras. Proc Natl Acad Sci U S A 90:5539-5545.
45. ras Blood 84:3435-3439.
46. Kim E, Ambroziak P, Otto JC, Taylor B, Ashby M, Shannon K, Casey PJ, Young SG. 1999. Disruption of the mouse Rce1 gene results in defective Ras processing and mislocalization of Ras within cells. J Biol Chem 274: 8383-8390.
47. ras, inhibition of cell proliferation and morphological changes. Oncogene 11:325-335.
48. Klose A, Ahmadian MR, Schuelke M, Scheffzek K, Hoffmeyer S, Gewies A, Schmitz F, Kaufmann D, Peters H, Wittinghofer A, Nurnberg P. 1998. Selective disactivation of neurofibromin GAP activity in neurofibromatosis type 1. Hum Mol Genet 7: 1261-1268.
49. Kohl NE, Conner MW, Gibbs JB, Graham SL, Hartman GD, Oliff A. 1995a. Development of inhibitors of protein farnesylation as potential chemotherapeutic agents. J Cell Biochem 22:145-150.
50. Kohl NE, Omer CA, Conner MW, Anthony NJ, Davide JP, DeSolms J, Giuliani EA, Gomez RP, Graham SL, Hamilton K, Handt LK, H. G.D., Koblan KS, Kral AM, Miller PJ, Mosser SD, O'Neill TJ, Rands E, Schaber MD, Gibbs JB, Oliff A. 1995b. Inhibition of farnesyltransferase induces regression of mammary and salivary carcinomas in ras transgenic mice. Nat Med 1:792-797.
51. Largaespada DA, Brannan CI, Jenkins NA, Copeland NG. 1996. Nf1 deficiency causes Ras-mediated granulocyte-macrophage colony stimulating factor hypersensitivity and chronic myeloid leukemia. Nature Genet 12:137-143.
52. Leevers S, Peterson H, Marshall C. 1994. Requirement for Ras in Raf activation is overcome by targeting Raf to the plasma membrane. Nature 369:411-414.
53. Legius E, Marchuk DA, Collins FS, Glover TW. 1993. Somatic deletion of the neurofibromatosis type 1 gene in a neurofibrosarcoma supports a tumour suppressor gene hypothesis. Nature Genet 3:122-126.
54. Li N, Batzer A, Daly R, Yajnik V, Skolnik E, Chardin P, Bar-Sagi D, Margolis B, Schlessinger J. 1993. Guanine-nucleotide-releasing factor hSos1 binds to Grb2 and links receptor tyrosine kinases to Ras signalling. Nature 363:85-88.
55. Li Y, Bollag G, Clark R, Stevens J, Conroy L, Fults D, Ward K, Friedman E, Samowitz W, Robertson M, Bradley P, McCormick F, White R, Cawthon R. 1992. Somatic mutations in the neurofibromatosis 1 gene in human tumors. Cell 69:275-281.
56. Lloyd AC, Obennuller F, Staddon S, Barth CF, McMahon M, Land H. 1997. Cooperating oncogenes converge to regulate cyclin/cdk complexes. Genes Dev 11:663-677.
57. Mahgoub N, Taylor B, Le Beau M, Gratiot M, Carlson K, Jackts T, Shannon KM. 1997. Effects of farneysl transferase inhibitor (FT1) L744,832 in a RAS-activated murine myeloid leukemia model. Blood 90(suppl 1): 497a.
58. Mangues R, Corral T, Kohl NE, Symmans, WF, Lu S, Malumbresm M, Gibbs JB. Oliff A, Pellicer A. 1998. Antitumor effect of a farnesyl protein transferase inhibitor in mammary and lymphoid tumors overexpressing N-ras in transgenic mice. Cancer Res 58: 1253-1259.
59. Marchuk DA, Saulino AM, Tavakkol R, Swaroop M, Wallace MR, Andersen LB, Mitchell AL, Gutmann DH, Boguski M, Collins FS. 1991. cDNA cloning of the type 1 neurofibromatosis gene: complete sequence of the NF1 gene product, Genomics 11:931-940.
60. Marshall C. 1995. Specificity of receptor tyrosine kinase signaling: transient versus sustained extracellular signal-regulated kinase activation. Cell 80:179-185.
61. Martegani E, Vanoni M, Zippel R, Coccetti P, Brambilla R, Ferrari C, Sturani E, Alberghina L. 1992. Cloning by functional complementation of a mouse cDNA encoding a homologue of CDC25, a Saccharomyces cerevisiae RAS activator. EMBO J 11:2151-2157.
62. Mattingly RR, Macara IG. 1996. Phosphorylation-dependent activation of the Ras-GRF/CDC25Mm exchange factor by muscarinic receptors and G-protein β γ subunits. Nature 382:268-272.
63. Moodie SA, Willumsen BM, Weber MJ, Wolfman A. 1993. Complexes of Ras-GTP with Raf-1 and mitogen-activated protein kinase kinase. Science 260:1658-1661.
64. Moores SL, Schaber MD, Mosser SD, Rands E, O'Hara MB, Garsky VN, Marshall MS, Pompliano DL, Gibbs JB. 1991. Sequence dependence of protein isoprenylation. J Biol Chem 266:14603-14610.
65. Noda M, Ko M, Ogura A. 1985. Sarcoma viruses carrying the ras oncogene activate differentiation-associated properties of a neuronal cell line. Nature 318:73-75.
66. Pouting CP, Benjamin DR. 1996. A novel family of Ras-binding domains. Trends Biochem Sci 21:422-425.
67. Robinson LC, Gibbs JB, Marshall MS. Sigal IS, Tatchell K. 1987. CDC25: a component of the RAS-adenylate cyclase pathway in Saccharomyces cerevisiae. Science 235:1218-1221.
68. Rodriguez-Viciana P, Warne PH, Dhand R, Vanhaesebroeck B, Gout I, Fry MJ, Waterfield MD, Downward J. 1994. Phosphatidylinositol-3-OH kinase as a direct target of Ras. Nature 370:527-532.
69. Rodriguez-Viciana P, Warne PH, Khwaja A, Marte BM, Pappin D, Das P, Waterfield MD, Ridley A, Downward J. 1997. Role of phosphoinositide 3-OH kinase in cell transformation and control of the actin cytoskeleton by Ras. Cell 89:457-467.
70. Rozakis-Adcock M, Fernley R, Wade J, Pawson T, Bowtell D. 1993. The SH2 and SH3 domains of mammalian Grb2 couple the EGF receptor to the Ras activator mSos1. Nature 363:83-85.
71. Sawada S, Florell S, Purandare S, Ota M, Stephens K, Viskochil D. 1996. Identification of NF1 mutations in both alleles of a dermal neurofibroma. Nature Genet 14:110-112.
72. Scheffzek K, Ahmadian MR, Kabsch W, Wiesmuller L, Lautwein A, Schmitz F, Wittinghofer A. 1997. The Ras-RasGAP complex: structural basis for GTPase activation and its loss in oncogenic Ras mutants [see comments]. Science 277:333-338.
73. Scheffzek K, Ahmadian MR, Wiesmuller L, Kabsch W, Stege P, Schmitz F, Wittinghofer A. 1998. Structural analysis of the GAP-related domain from neurofibroma and its implications. EMBO J 17:4313-4327.
74. Schmidt WK, Tam A, Fujimura-Kamada K, Michaelis S. 1998. Endoplasmic reticulum membrane localization of Rcelp and Ste24p, yeast proteases involved in carboxyl-terminal CAAX protein processing and amino-terminal a-factor cleavage. Proc Natl Acad Sci USA 95:11175-11180.
75. Sewing A, Wiseman B, Lloyd AC, Land H. 1997. High-intensity Raf signal causes cell cycle arrest mediated by p21Cip1. Mol Cell Biol 17:5588-5597.
76. Shannon KM, O'Connell P, Martin GA, Paderanga D, Olson K, Dinndorf P, McCormick F. 1994. Loss of the normal NF1 allele from the bone marrow of children with type 1 neurofibromatosis and malignant myeloid disorders. N Engl J Med 330:597-601.
77. Shou C, Farnsworth CL, Neel BG, Feig LA. 1992. Molecular cloning of cDNAs encoding a guanine-nucleotide-releasing factor for Ras p21. Nature 358:351-354.
78. Side L, Taylor B, Cayouette M, Connor E, Thompson P, Luce M, Shannon K. 1997. Homozygous inactivation of the NF1 gene in bone marrow cells from children with neurofibromatosis type 1 and malignant myeloid disorders. N Engl J Med 336: 1713-1720.
79. Silva AJ, Frankland PW, Marowitz Z, Friedman E, Lazlo G, Cioffi D, Jacks T, Bourtchuladze R. 1997. A mouse model for the learning and memory deficits associated with neurofibromatosis type I. Nature Genet 15:281-284.
80. Simon MA, Bowtell DDL, Dodson GS, Laverty TR, Rubin GM. 1991. Ras1 and a putative guanine nucleotide exchange factor perform crucial steps in signaling by the sevenless protein tyrosine kinase. Cell 67:701-716.
81. Skuse GR, Kosciolek BA, Rowley PT. 1989. Molecular genetic analysis of tumors in von Recklinghausen neurofibromatosis: loss of heterozygosity for chromosome 17. Genes Chromosom Cancer 1:36-11.
82. Stokoe D, MacDonald S, Cadwallader K, Symons M, Hancock J. 1994. Activation of Raf as a result of recruitment to the plasma membrane. Science 264:1463-1466.
83. Stokoe D, Stephens LR, Copeland T, Gaffney PR, Reese CD, Painter GF, Holmes AB, McCormick F, Hawkins PT. 1997. Dual role of phosphatidylinositol 3,4,5 trisphosphate in the activation of protein kinase B. Science 277:567-570.
84. The I, Hannigan GE, Cowky GS, Reginald S, Zhong Y, Gusella JF, Hariharan IK, Bernards A. 1997. Rescue of a Drosophila NF1 mutant phenotype by protein kinase A. Science 276:791-794.
85. The 1, Murthy AE, Hannigan GE, Jacoby LB, Menon AG, Gusella JF, Bernanrds A. 1993. Neurofibromatosis type 1 gene mutations in neuroblastoma. Nature Genet 3:62-66.
86. Tognon CE, Kirk HE, Passmore LA, Whitehead IP, Der CJ, Kay RJ. 1998. Regulation of RasGRP via a phorbol ester-responsive C1 domain. Mol Cell Biol 18:6995-7008.
87. Van Aelst L, Barr M, Marcus S, Polverino A, Wigler M. 1993. Complex formation between RAS and RAF and other protein kinases. Proc Natl Acad Sci U S A 90:6213-6217.
88. Venkatachalam S, Shi YP, Jones SN, Vogel H, Bradley A, Pinkel D, Donehower LA. 1998. Retention of wild-type p53 in tumors from p53 heterozygous mice: reduction of p53 dosage can promote cancer formation. EMBO J 17:4657-4667.
89. Viskochil D, Buchberg AM, Xu G, Cawthon RM, Stevens J, Wolt J. RK, Culver M, Carey JC, Copeland NG, Jenkins NA, White R, O'Connell P. 1990. Deletions and a translocation interrupt a cloned gene at the neurofibromatosis type 1 locus. Cell 62:187-192.
90. Vlahos CJ, Matter WF, Hui KY, Brown RF. 1994. A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002). J Biol Chem 269:5241-5248.
91. Vogel KS, Brannan CI, Jenkins NA, Copeland NG, Parada L. 1995. Loss of neurofibromin results in neurotropin-independent survival of embryonic sensory and sympathetic neurons. Cell 82:733-742.
92. Vojtek AB, Hollenberg SM, Cooper JA. 1993. Mammalian Ras interacts directly with the serine/threonine kinase Raf. Cell 74:205-214.
93. Wallace M, Marchuk D, Andersen L, et al. 1990. Type 1 neurofibromatosis gene: identification of a large transcript disrupted in three NF1 patients. Science 249:181-186.
94. Warne PH, Viciana PR, Downward J. 1993. Direct interaction of Ras and the amino-terminal region of Raf-1 in vitro. Nature 364:352-355.
95. Wei W, Mosteller RD, Sanyal P, Gonzales E, McKinney D, Dasgupta D, Li P, Liu BX, Broek D. 1992. Identification of a mammalian gene structurally and functionally related to the CDC25 gene of Saccharomyces cerevisiae. Proc Natl Acad Sci U S A 89: 7100-7104.
96. White MA, Nicolette C, Minden A, Polverino A, Van Aelst L, Karin M, Wigler MH. 1995. Multiple Ras functions can contribute to mammalian cell transformation. Cell 80:533-541.
97. Wittinghofer A. 1998. Signal transduction via Ras. Biol Chem 379:933-937.
98. Xu G, O'Connell P, Viskochil D, Cawthon R, Robertson M, Culver M, Dunn D, Stevens J, Gesteland R, White R, Weiss R. 1990. The neurofibromatosis type 1 gene encodes a protein related to GAP. Cell 62:599-608.
99. Xu W, Mulligan L, Ponder MA, Liu L, Smith BA, Mathew CG, Ponder BA. 1992. Loss of alleles in pheochromocytomas from patients with type 1 neurofibromatosis. Genes Chromosom Cancer 4:337-341.
100. Yan N, Ricca C, Fletcher J, Glover T, Seizinger BR, Manne V. 1996. Farnesyltransferase inhibitors block the neurofibromatosis type 1 (NF1) malignant phenotype. Cancer Res 55:3569-3575.
101. Yao R, Cooper GM. 1995. Requirement for phosphatidylinositol-3 kinase in the prevention of apoptosis by nerve growth factor. Science 267:2003-2006.
102. Zhang XF, Settleman J, Kyriakis JM, Takeuchi-Suzuki E, Elledge SJ, Marshall MS, Bruder JT, Rapp UR, Avruch J. 1993. Normal and oncogenic p21ras proteins bind to the amino-terminal regulatory domain of c-Raf-1. Nature 364:308-313.
103. Zhang Y, Vik TA, Ryder JW, Srour, EF, Jacks T, Shannon K, Clapp DW. 1998. Nf1 regulates hematopoietic progenitor cell growth and Ras signaling in response to multiple cytokines. J Exp Med 187:1893-1902.